Hemab Therapeutics Holdings, Inc.

What they do

Hemab discovers and develops therapies for serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. Its lead asset, sutacimig, is a bispecific antibody in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency. HMB-002 is a monovalent antibody in Phase 1/2 for subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-003 is a preclinical non-hormonal peptide plasmin inhibitor initially targeting heavy menstrual bleeding.

Revenue drivers

• No product revenue — The company has no approved products and has not generated any revenue from product sales.
• Sutacimig — Lead clinical asset; no revenue today, with a Phase 3 pivotal trial in Glanzmann thrombasthenia planned to start in 2H 2026.
• HMB-002 — Second clinical-stage asset in Phase 1/2 for Von Willebrand Disease; no revenue today.
• HMB-003 — Preclinical plasmin inhibitor unveiled for heavy menstrual bleeding and other bleeding settings; no revenue today.

Recent performance

Net losses were $46.8 million for the six months ended June 30, 2026, compared with $27.5 million for the same period in 2025. As of June 30, 2026, Hemab had total assets of $467.8 million, total liabilities of $13.5 million, shareholder equity of $454.3 million, and cash and equivalents of $237.4 million. The company reported an accumulated deficit of $228.7 million as of June 30, 2026. It has received aggregate gross proceeds of approximately $692.7 million since inception, including approximately $317.2 million in net IPO proceeds.

Strategy

Hemab is advancing sutacimig toward a planned Phase 3 pivotal trial in Glanzmann thrombasthenia in 2H 2026, following FDA endorsement of the clinical data package as sufficient to proceed. It is also progressing HMB-002 in Von Willebrand Disease and HMB-003 in preclinical development for heavy menstrual bleeding. The company expects expenses to increase as it advances clinical development, pursues later-stage trials, expands research and preclinical activities, establishes manufacturing capabilities, and seeks regulatory approvals. Management has stated it anticipates multiple value-driving clinical data events in 2026, 2027, and beyond.

Risks

• No approved products or revenue — Hemab has no approved products and has not generated any product revenue, so it depends on external financing to fund operations.
• Substantial operating losses — The company reported net losses of $46.8 million for the six months ended June 30, 2026, and an accumulated deficit of $228.7 million.
• Clinical and regulatory risk — Sutacimig, HMB-002, and HMB-003 remain investigational and may fail to demonstrate safety or efficacy or obtain marketing approval.
• Safety events in sutacimig trial — Three participants in the Phase 1/2 trial experienced Grade 2 thromboembolic events, and the Phase 3 dose and regimen were selected to avoid high peak exposures associated with those events.

Outlook

Management plans to initiate a Phase 3 pivotal trial of sutacimig in Glanzmann thrombasthenia in the second half of 2026. The company expects to continue advancing HMB-002 in Von Willebrand Disease and HMB-003 in preclinical development, with additional updates expected later this year. Hemab anticipates multiple value-driving clinical data events in 2026, 2027, and beyond, and expects operating expenses and net losses to increase substantially as development advances.